GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of 8 months in and amylin is still the thing I get wrong — 18 comments in the full submission. View in context.
214
c/cagrilintide·submitted 3 months ago by u/ms_fragmenter

8 months in and amylin is still the thing I get wrong

Cautionbranch of 8 comments

Check-in as promised in the title: 8 months in and amylin is still the thing I get wrong. 8 months. Those are measured, not estimated, and not rounded up in my favour. Kept a log purely because so few people are logging this one. It is one person and it is not data. Asked a question here that turned out to be based…

Read the full submission and all 18 comments →

This branch

8 comments, started 3 months ago
u/noor_ivaturi19 points·3 months ago

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

replysharereportpermalink
u/ms_fragmenterOP14 points·3 months ago

amylin analogue, different receptor family, different story

replysharereportpermalink
u/ms_fragmenterOP8 points·3 months ago

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

replysharereportpermalink
u/ms_fragmenterOP5 points·3 months ago

amylin and GLP-1 are not redundant pathways

replysharereportpermalink
u/ice_pack_auditcold chain1 point·3 months ago·edited

this is a less-travelled board and the evidence base shows it

replysharereportpermalink
u/wrong_network_w4 points·3 months ago

long-acting amylin is the whole point of the molecule

replysharereportpermalink
u/nadia_bakker3 points·3 months ago

nausea profile in the combination trials is the thing to read carefully

replysharereportpermalink
u/rekha_mwangi5 points·3 months ago

I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →